Table 1.
Baseline characteristics of 15.715 included patients with esophageal or gastric cancer
| Esophageal cancer | Gastric cancer | |||||
|---|---|---|---|---|---|---|
| 2017–2019 | 2020 | p-value | 2017–2019 | 2020 | p-value | |
| Patients | 7568 | 2391 | 4325 | 1431 | ||
| Sex | ||||||
| Female | 1945 (25.7) | 664 (27.8) | 0.048 | 1549 (35.8) | 515 (36.0) | 0.931 |
| Male | 5623 (74.3) | 1727 (72.2) | 2776 (64.2) | 916 (64.0) | ||
| Age | ||||||
| < 60 years | 1208 (16.0) | 367 (15.3) | 0.715 | 742 (17.2) | 272 (19.0) | 0.203 |
| 60–74 years | 3978 (52.6) | 1256 (52.5) | 1678 (38.8) | 527 (36.8) | ||
| > 74 years | 2382 (31.5) | 768 (32.1) | 1905 (44.0) | 632 (44.2) | ||
| Histology | ||||||
| Adenocarcinoma | 5542 (73.2) | 1738 (72.7) | 0.866 | 4281 (99.0) | 1410 (98.5) | 0.210 |
| Squamous cell carcinoma | 1966 (26.0) | 633 (26.5) | 0 (0.0) | 0 (0.0) | ||
| Other | 60 (0.8) | 20 (0.8) | 44 (1.0) | 21 (1.5) | ||
| Stage | ||||||
| Early carcinoma | 207 (2.7) | 67 (2.8) | 0.119 | 94 (2.2) | 32 (2.2) | 0.268 |
| Potentially curable | 4783 (63.2) | 1462 (61.1) | 1981 (45.8) | 621 (43.4) | ||
| Incurable | 2572 (34.0) | 857 (35.8) | 2246 (51.9) | 778 (54.4) | ||
| Unknown | 6 (0.1) | 5 (0.2) | 4 (0.1) | 0 (0.0) | ||
| Comorbidities | ||||||
| 0 | 3203 (44.6) | 1056 (45.0) | 0.818 | 1790 (44.1) | 625 (44.3) | 0.844 |
| 1 | 2360 (32.8) | 755 (32.1) | 1326 (32.7) | 468 (33.2) | ||
| 2 or more | 1623 (22.6) | 538 (22.9) | 945 (23.3) | 318 (22.5) | ||
| Performance status | ||||||
| ECOG 0 | 2222 (38.8) | 741 (38.2) | 0.057 | 958 (34.0) | 374 (35.8) | 0.031 |
| ECOG 1 | 2369 (41.4) | 764 (39.4) | 1129 (40.1) | 366 (35.1) | ||
| ECOG 2 | 745 (13.0) | 273 (14.1) | 428 (15.2) | 173 (16.6) | ||
| ECOG 3 or 4 | 385 (6.7) | 160 (8.3) | 302 (10.7) | 131 (12.5) | ||
All data are represented as n (%). Counts for 2017–2019 are shown as the sum of the 3 years. Percentages for 2017–2019 are shown as the average of the 3 years